Inspra contains eplerenone, a blocker of aldosterone binding at the mineralocorticoid receptor. INSPRA is indicated to improve survival of stable patients with left ventricular systolic dysfunction (ejection fraction 40%) and clinical evidence of congestive heart failure after an acute myocardial infarction. INSPRA tablets contain 25 mg or 50 mg of eplerenone. The principal risk of INSPRA is hyperkalemia. Hyperkalemia can cause serious, sometimes fatal, arrhythmias. This risk can be minimized by patient selection, avoidance of certain concomitant treatments, and monitoring. For patient selection and avoidance of certain concomitant medications. INDICATIONS AND USAGE Congestive Heart Failure Post-Myocardial Infarction INSPRA is indicated to improve survival of stable patients with left ventricular systolic dysfunction (ejection fraction £40%) and clinical evidence of congestive heart failure after an acute myocardial infarction. INSPRA is indicated for the treatment of hypertension. INSPRA may be used alone or in combination with other antihypertensive agents.

Inspra Side Effects:

In the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS), the overall incidence of adverse events reported with eplerenone (78.9%) was similar to placebo (79.5%). The discontinuation rate due to adverse events in these studies was 4.4% for patients receiving eplerenone and for 4.3% patients receiving placebo. Adverse events reported below are taken from EPHESUS and are those with suspected relationship to treatment and in excess of placebo, or are serious and significantly in excess of placebo. Adverse events are listed by body system and absolute frequency. Frequencies are defined as: common> 1/100, < 1/10; uncommon> 1/1000, < 1/100. Blood and lymphatic system disorders- Uncommon: eosinophilia. Metabolism and nutrition disorders-Common: hyperkalaemia. Uncommon: dehydration, hypercholesterolaemia, hypertriglyceridaemia, hyponatraemia. Psychiatric disorders-Uncommon: insomnia. Nervous system disorders-Common: dizziness.Uncommon: headache. Cardiac disorders-Uncommon: atrial fibrillation, myocardial infarction, left cardiac failure. Vascular disorders-Common: hypotension. Uncommon: postural hypotension, arterial leg thrombosis. Respiratory, thoracic and mediastinal disorders-Uncommon: pharyngitis. Gastrointestinal disorders-Common: diarrhoea, nausea. Uncommon: flatulence, vomiting. Skin and subcutaneous tissue disorders-Uncommon: pruritus, increased sweating. Musculoskeletal and connective tissue disorders-Uncommon: back pain, leg cramps. Renal and urinary disorders-Common: abnormal renal function. General disorders and administration site conditions-Uncommon: asthenia, malaise. Investigations-Uncommon: increased BUN, creatinine increase Infections and infestations-Uncommon: pyelonephritis. In EPHESUS, there were numerically more cases of stroke in the elderly group (> 75 years old). There was however no statistical significant difference between the occurrence of stroke in the eplerenone (30) vs placebo (22) groups. Drug-drug interaction studies were conducted with a 100 mg dose of eplerenone. Eplerenone is metabolized primarily by CYP3A4. A potent inhibitor of CYP3A4 (ketoconazole) caused increased exposure of about 5-fold while less potent CYP3A4 inhibitors (erythromycin, saquinavir, verapamil, and fluconazole) gave approximately 2- fold increases. Grapefruit juice caused only a small increase (about 25%) in exposure.

The recommended dose of INSPRA is 50 mg once daily. Treatment should be initiated at 25 mg once daily and titrated to the target dose of 50 mg once daily preferably within 4 weeks as tolerated by the patient. INSPRA may be administered with or without food. Serum potassium should be measured before initiating INSPRA therapy, within the first week and at one month after the start of treatment or dose adjustment. Serum potassium should be assessed periodically thereafter. Factors such as patient characteristics and serum potassium levels may indicate that additional monitoring is appropriate. INSPRA (Eplerenone) binds to the mineralocorticoid receptor and blocks the binding of aldosterone, a component of the renin-angiotensin-aldosterone-system (RAAS). Aldosterone synthesis, which occurs primarily in the adrenal gland, is modulated by multiple factors, including angiotensin II and non-RAAS mediators such as adrenocorticotropic hormone (ACTH) and potassium. Aldosterone binds to mineralocorticoid receptors in both epithelial (e.g., kidney) and nonepithelial (e.g., heart, blood vessels, and brain) tissues and increases blood pressure through induction of sodium reabsorption and possibly other mechanisms. INSPRA (Eplerenone) has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of INSPRA (Eplerenone).